Sam Slutsky
Stock Analyst at LifeSci Capital
(4.97)
# 88
Out of 5,010 analysts
699
Total ratings
49.8%
Success rate
44.7%
Average return
Main Sectors:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $22.68 → $22.72 | $11.86 | +91.53% | 12 | Sep 30, 2026 | |
| DBVT DBV Technologies | Maintained: Buy | $45 | $11.55 | +289.61% | 14 | Sep 30, 2026 | |
| OBX Obsidian Therapeutics | Reiterated: Buy | $43 | $14.58 | +194.92% | 2 | Sep 29, 2026 | |
| CLDX Celldex Therapeutics | Rated: Buy | $56 → $64 | $31.64 | +102.28% | 45 | Sep 28, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $53 | $33.46 | +58.40% | 74 | Sep 26, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $8 | $2.90 | +175.86% | 25 | Sep 26, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $175 | $82.15 | +113.02% | 25 | Sep 23, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $170 → $168 | $98.50 | +70.56% | 36 | Sep 22, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $16 | $8.54 | +87.35% | 46 | Sep 19, 2026 | |
| DMRA Damora Therapeutics | Reiterated: Buy | $45 | $20.66 | +117.81% | 9 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $31.66 | +73.72% | 52 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 | $29.54 | +45.57% | 28 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $8.91 | +528.51% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $84.72 | +36.92% | 59 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $18.16 | +147.80% | 2 | Sep 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.3175 | - | 23 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $99 → $98 | $31.17 | +214.40% | 3 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $70 | $46.51 | +50.51% | 38 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $70.52 | +53.15% | 34 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.35 | - | 29 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.85 | +170.27% | 33 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.60 | +515.38% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $236 | $139.00 | +69.78% | 25 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.16 | $0.791 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.32 | n/a | 23 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $33.21 → $20.41 | $2.31 | n/a | 30 | Apr 18, 2023 |
Eupraxia Pharmaceuticals Inc.
Sep 30, 2026
Maintained: Buy
Price Target: $22.68 → $22.72
Current: $11.86
Upside: +91.53%
DBV Technologies
Sep 30, 2026
Maintained: Buy
Price Target: $45
Current: $11.55
Upside: +289.61%
Obsidian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $43
Current: $14.58
Upside: +194.92%
Celldex Therapeutics
Sep 28, 2026
Rated: Buy
Price Target: $56 → $64
Current: $31.64
Upside: +102.28%
Immunovant
Sep 26, 2026
Reiterated: Buy
Price Target: $53
Current: $33.46
Upside: +58.40%
Pyxis Oncology
Sep 26, 2026
Reiterated: Buy
Price Target: $8
Current: $2.90
Upside: +175.86%
Oruka Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $175
Current: $82.15
Upside: +113.02%
ABIVAX Société Anonyme
Sep 22, 2026
Reiterated: Buy
Price Target: $170 → $168
Current: $98.50
Upside: +70.56%
Olema Pharmaceuticals
Sep 19, 2026
Reiterated: Buy
Price Target: $16
Current: $8.54
Upside: +87.35%
Damora Therapeutics
Sep 18, 2026
Reiterated: Buy
Price Target: $45
Current: $20.66
Upside: +117.81%
Sep 15, 2026
Reiterated: Buy
Price Target: $55
Current: $31.66
Upside: +73.72%
Sep 14, 2026
Reiterated: Buy
Price Target: $43
Current: $29.54
Upside: +45.57%
Sep 11, 2026
Reiterated: Buy
Price Target: $56
Current: $8.91
Upside: +528.51%
Sep 8, 2026
Reiterated: Buy
Price Target: $116
Current: $84.72
Upside: +36.92%
Sep 5, 2026
Reiterated: Buy
Price Target: $45
Current: $18.16
Upside: +147.80%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.3175
Upside: -
Aug 19, 2026
Reiterated: Buy
Price Target: $99 → $98
Current: $31.17
Upside: +214.40%
Aug 8, 2026
Rated: Buy
Price Target: $60 → $70
Current: $46.51
Upside: +50.51%
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $70.52
Upside: +53.15%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.35
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.85
Upside: +170.27%
Aug 5, 2026
Reiterated: Buy
Price Target: $16
Current: $2.60
Upside: +515.38%
Aug 5, 2026
Reiterated: Buy
Price Target: $225 → $236
Current: $139.00
Upside: +69.78%
Dec 14, 2023
Reiterated: Hold
Price Target: $1.16
Current: $0.791
Upside: n/a
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $7.32
Upside: n/a
Apr 18, 2023
Upgraded: Hold
Price Target: $33.21 → $20.41
Current: $2.31
Upside: n/a